BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17591832)

  • 1. Cetuximab in squamous cell head and neck carcinomas.
    Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab and radiotherapy for head and neck cancer.
    Posner MR; Wirth LJ
    N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab plus radiotherapy for head and neck cancer.
    Armstrong JG
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
    Teoh DC; Rodger S; Say J; Hartley A
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising new advances in head and neck radiotherapy.
    Harari PM
    Ann Oncol; 2005; 16 Suppl 6():vi13-vi19. PubMed ID: 15987991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab plus radiotherapy for head and neck cancer.
    Cengiz M; Yildiz F; Genc M
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710908
    [No Abstract]   [Full Text] [Related]  

  • 11. More on cetuximab in head and neck cancer.
    Mell LK; Weichselbaum RR
    N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab plus radiotherapy for head and neck cancer.
    Ho AC
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16707760
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
    Chan A; Teoh D; Sanghera P; Hartley A
    Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.